PositiveNewsCorner

Article by Paridhi Sharma

For the first time, a drug trial has shown 100% eradication of cancer in patients at Memorial Sloan Kettering Cancer Center in Manhattan, US. Dostarlimab, an antibody-based drug that functions as a surrogate for antibodies in the human body has recently proved its effectiveness in combatting colorectal cancer.

18 patients suffering from colorectal cancer (same stage of cancer) were under clinical trials of this drug for 6 months and after interpreting the results obtained from physical examination, endoscopy, positron emission tomography or PET scans, or MRI scans, the experts stated that the malignancy is undetectable in the patients.

Based on the fact that cancer had vanished, shows that this medicine has the potential to be a ‘possible’ cancer cure for one of the most lethal tumours. According to doctors, the patients, during the trial, took Dostarlimab every three weeks for six months. This is “the first time this has happened in the history of cancer,” according to Dr. Luis A. Diaz J. of Memorial Sloan Kettering Cancer Center in New York.

Tumor vanished in all 12 rectal cancer patients during a drug trial.

The trial was conducted for 6 months.

The cost of the drug (in trial phase) is approximately Rs 8.55 lakh.

Dr Alan P. Venook, who is a colorectal cancer specialist at the University of California, said that the complete remission in every single patient is “unheard-of”. He hailed the research as “world-first”.”

There were a lot of happy tears,” said Oncologist Dr Andrea Cercek, describing the moment patients found out they were cancer-free as quoted by New York Times.

This is indeed a massive breakthrough for making the patients “cancer-free”. It shows a really promising future for curing such deadly tumours.